Cancer

Health Angus Chen

With younger women getting breast cancer, national panel lowers mammogram screening age to 40

The Readout Meghana Keshavan

STAT Plus: House bill aimed at Chinese biotechs is advancing 

Biotech Adam Feuerstein

STAT Plus: Ono Pharmaceutical to acquire Deciphera Pharma, maker of cancer drugs, for $2.4 billion

Exclusive Adam Feuerstein

STAT Plus: New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition

Letters to the editor Patrick Skerrett

STAT readers respond to First Opinion essays on site-neutral payments, free medical school tuition, and more

The Readout Elaine Chen

STAT Plus: A spending frenzy on obesity drugs

First Opinion Folasade P. May

Balancing hope and reality: The promise and peril of blood-based colorectal cancer screening

Biotech Jason Mast

STAT Plus: Day One drug for common childhood brain tumor approved by FDA

First Opinion Peter J. Pitts and Timothy R. Franson

Bashing accelerated approval isn’t supported by the data

In the Lab Angus Chen

STAT Plus: Dana-Farber retracts string of studies in systematic review of data integrity

Exclusive Allison DeAngelis

STAT Plus: Cancer vaccine startup launches with $54 million, Spark veteran as CEO

Hospitals Bob Herman

STAT Plus: Mass General Brigham is ready to move on without Dana-Farber, CEO says

The Readout Damian Garde

STAT Plus: Gas prices are hurting biotech

In the Lab Angus Chen

STAT Plus: When a cancer drug fails, oncologists often fly blind. A precision technique might light the way

The Readout Meghana Keshavan

STAT Plus: AskBio CSO steps down, has new project in stealth mode

Biotech Angus Chen

STAT Plus: Cancer vaccines gain momentum, after years of disappointing results

Politics Jonathan Wosen

STAT Plus: NCI director expresses optimism about next era of cancer research, despite shrinking budget and brain drain

First Opinion David Ropeik

Cancer is a killer. So is the fear of it

Pharmalot Ed Silverman

STAT Plus: Biden administration urged to license prostate cancer drug patents in a bid to lower its cost

Insurance Tara Bannow

STAT Plus: MassMutual is rolling out free genetic testing for members, a dicey area for life insurers

In the Lab Angus Chen

STAT Plus: New liquid biopsy screening test for pancreatic cancer shows promise in early data

Biotech Matthew Herper

STAT Plus: WHO scientists question Grail’s plan for evaluating its multi-cancer Galleri blood test

Health Jonathan Wosen

STAT Plus: About half of cancer drugs given accelerated approval don’t show improved survival or quality of life

In the Lab Jonathan Wosen

STAT Plus: Cancer is rising among the young. Study suggests it’s because their cells are aging faster

First Opinion Patrick Skerrett

STAT readers on biotech and national security, liquid-only diets before colonoscopy, and the value of weight loss drugs

The Readout Meghana Keshavan

STAT Plus: New data on liquid biopsy for colorectal cancer detection still underwhelms

Biotech Andrew Joseph

STAT Plus: Genmab to buy ProfoundBio for $1.8 billion, the latest deal focused on targeted chemotherapies

Biotech Jason Mast

STAT Plus: Gritstone Bio says personalized cancer vaccine falls short in key trial

Health Care Inc. Tara Bannow

Why a bill meant to stop surprise medical bills hasn’t worked